摘要
目的:观察盐酸非索非那丁片联合辛芩颗粒治疗过敏性鼻炎的临床疗效及安全性。方法:将72例过敏性鼻炎患者根据就诊次序随机1:1分为治疗组和对照组,治疗组口服盐酸非索非那丁片60mg,bid+辛芩颗粒5g,tid;对照组口服盐酸非索非那丁片60mg,bid。2组疗程均为3周。治疗前、后进行疗效及安全性评定。结果:治疗组和对照组治疗后症状总积分分别为(0.12±0.20)分和(0.56±0.39)分,2组比较差异有统计学意义(P<0.05)。治疗组和对照组不良反应发生率分别为10.9%、11.1%,2组比较差异无统计学意义(P>0.05)。结论:盐酸非索非那丁片联合辛芩颗粒治疗过敏性鼻炎疗效确切,安全性好。
OBJECTIVE ： To observe the efficacy and safety of fexofenadine hydrochloride tablets and Xinqin Keli treated allergic rhinitis. METHODS： 72 patients with Allergic rhinitis were divided into experimental group（36 cases） and control group（36 cases） randomly. Experimental group used fexofenadine hydrochloride Tablets 60 mg, bid, and at the same time used Xinqin Keli 5 g, tid. While control group use fexofenadine hydrochloride tablets 60 mg, bid, And medication lasts 3 weeks. After treatment, the efficacy and safety were analyzed. RESULTS： The total symptom score in experimental group and control group was （0.12 ± 0.20） and （0.56± 0.39）after treatment, and that of the later was higher than that of the former statistically（P〈0.05）. The incidence of adverse drug reaction in experimental group was 10.9%, that of control group was 11.1%.The 2 groups were not significantly different （P〉0.05）. CONCLUSION： There were remarkable therapeutic effects and no serious adverse reaction of fexofenadine hydrochloride Tablets and Xinqin Keli on allergic rhinitis.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第40期3811-3812,共2页
China Pharmacy
